- |||||||||| centanafadine SR (EB-1020) / Otsuka
Journal: Treatment Preferences of Physicians Treating Adult Patients with Attention-Deficit/Hyperactivity Disorder (Pubmed Central) - Nov 18, 2024
Efficacy was the most important single attribute for physicians treating adult patients with ADHD in both the US and Canada; however, the risks of AEs taken together had greater relative importance than efficacy alone among US but not Canadian physicians. These findings highlight potential discrepancies in physician and patient preferences based on existing evidence and underscore the importance of shared decision-making, which may in turn increase patients' treatment satisfaction.
- |||||||||| atomoxetine / Generic mfg.
Review, Journal: Precision pharmacotherapy of atomoxetine in children with ADHD: how to ensure the right dose for the right person? (Pubmed Central) - Nov 14, 2024
Although there are notable gaps in achieving personalized dosing across multiple critical elements, the available evidence is helpful to endorse personalized dose adjustments based on TDM and CYP2D6 genotyping "whenever possible." We advocate for ongoing improvement and enhancement in clinical practice. Future advancements will rely on a deeper understanding of ADHD, facilitating more precise diagnoses and personalized treatment strategies.
- |||||||||| methylphenidate tablet / Generic mfg., atomoxetine / Generic mfg.
Clinical, Retrospective data, Review, Journal, Adverse events: Methylphenidate and Atomoxetine in Pregnancy and Possible Adverse Fetal Outcomes: A Systematic Review and Meta-Analysis. (Pubmed Central) - Nov 6, 2024
Evidence from this meta-analysis, which involves a substantial sample of pregnant women with and without ADHD, suggests the maintenance of methylphenidate or atomoxetine during pregnancy is safe, given that congenital anomalies and miscarriages did not appear to significantly increase. Further studies are recommended to support and confirm these findings.
- |||||||||| methylphenidate tablet / Generic mfg., atomoxetine / Generic mfg.
Journal: Precuneal hyperperfusion in patients with attention-deficit/hyperactivity disorder-comorbid nociplastic pain. (Pubmed Central) - Nov 1, 2024
The hyperperfusion in the precuneus was positively correlated with the CGI-S score and significantly reduced after treatment with MP (paired t-test, cluster-definition p < 0.005, cluster-extent threshold p < 0.05, with FWE correction). The finding of precuneal hyperperfusion may provide insight into the mechanisms of NP and help identify patients who would benefit most from ADHD medications.
- |||||||||| atomoxetine / Generic mfg.
Journal: Noradrenergic modulation of saccades in Parkinson's disease. (Pubmed Central) - Oct 28, 2024
Here, we studied the effect of 40?mg atomoxetine, a noradrenaline reuptake inhibitor, in 19 people with idiopathic Parkinson's disease using a single dose, randomized double-blind, crossover, placebo-controlled design...Our results provide new evidence to substantiate a role for noradrenergic modulation of saccades, and based on known circuitry, we advance the hypothesis that this reflects modulation at the level of the locus coeruleus-superior colliculus pathway. Given the potential for noradrenergic treatment of non-motor symptoms of Parkinson's disease and related conditions, the oculomotor system can support the assessment of cognitive effects without limb-motor confounds on task performance.
- |||||||||| venlafaxine / Generic mfg., atomoxetine / Generic mfg., trazodone ER / Generic mfg.
Phase classification, Enrollment change: Pharmacological Treatment Targeting Endotypic Traits of Obstructive Sleep Apnea (clinicaltrials.gov) - Oct 9, 2024
P4, N=132, Not yet recruiting,
The observed variations in adverse events emphasize the need for ongoing surveillance to mitigate potential cardiovascular risks and enhance patient safety and treatment outcomes. Phase classification: P1 --> P4 | N=66 --> 132
- |||||||||| atomoxetine / Generic mfg.
Trial completion, Surgery, Bariatric surgery: Bariatric Surgery and Pharmacokinetics of Atomoxetine (clinicaltrials.gov) - Oct 8, 2024
P=N/A, N=12, Completed,
Phase classification: P1 --> P4 | N=66 --> 132 Recruiting --> Completed
- |||||||||| Comtan (entacapone) / Novartis, Orion Corp
Trial completion date, Trial primary completion date: Treatment of Orthostatic Intolerance (clinicaltrials.gov) - Oct 1, 2024
P1/2, N=150, Active, not recruiting,
No abstract available Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2027
- |||||||||| atomoxetine / Generic mfg.
Preclinical, Journal: Assessing the stability of responding of male mice in the touchscreen 5 choice serial reaction time task: Focus on premature responding. (Pubmed Central) - Sep 30, 2024
Premature responding was subsequently tested following administration of pharmacological agents known to bi-directionally affect attention and impulsive action-cocaine, atomoxetine, and yohimbine...Yohimbine had no effect on premature responding in the baseline task but decreased premature responding when tested using an elongated inter-trial interval. Overall, these results highlight that the touch screen adaptation of the 5CSRTT is an effective method for longitudinal testing of attention and impulsive action and remains sensitive to performance changes arising from repeated pharmacological and behavioral challenges.
- |||||||||| atomoxetine / Generic mfg.
Enrollment change, Trial termination, Surgery, Bariatric surgery: RYGB: Orthostatic Intolerance After Bariatric Surgery (clinicaltrials.gov) - Sep 26, 2024
P1, N=10, Terminated,
Weight Loss clinic (VWL) was closed for IN person visits. We could not recruit any participant for Non surgical weight loss category.
- |||||||||| methylphenidate tablet / Generic mfg.
Journal: Exploring Methylphenidate-Induced Intraocular Pressure: A Cautionary Tale in Pediatric ADHD Management. (Pubmed Central) - Sep 24, 2024
Notably, the patient's high hyperopia contributed to the impact of MTX on IOP, suggesting the need for cautious use in susceptible individuals. This case underscores the importance of individualized treatment strategies, particularly in attention deficit hyperactivity disorder patients with family history and additional eye findings, emphasizing safety and comprehensive patient care.
- |||||||||| atomoxetine / Generic mfg.
Preclinical, Journal: Pharmacological Modulation of Cognitive Test Solution in Mice of Two Genotypes. (Pubmed Central) - Sep 24, 2024
which blocks the noradrenaline reuptake, and of 'non-benzodiazepine" anxiolytic afobazol was different. The success of solutions increased in mice selected for this test "non-solution": and decreased or was inefficient in mice, selected for successful solution of object permanence cognitive test.
- |||||||||| isoflurane / Generic mfg.
Preclinical, Journal: Dopaminergic psychostimulants cause arousal from isoflurane-induced sedation without reversing memory impairment in rats. (Pubmed Central) - Sep 21, 2024
Low-dose isoflurane impairs visuospatial working memory in a nondurable and delay-independent manner that potentially implicates non-hippocampal structures in isoflurane-induced memory deficits. Dopaminergic psychostimulants counteracted sedation but did not reverse memory impairments, suggesting that isoflurane-induced amnesia and isoflurane-induced sedation have distinct underlying mechanisms that can be antagonised independently.
- |||||||||| atomoxetine / Generic mfg.
Trial completion, Trial completion date: Dialectical Behavioral Therapy Skills for Impulsive Aggression (clinicaltrials.gov) - Sep 18, 2024
P=N/A, N=66, Completed,
Dopaminergic psychostimulants counteracted sedation but did not reverse memory impairments, suggesting that isoflurane-induced amnesia and isoflurane-induced sedation have distinct underlying mechanisms that can be antagonised independently. Active, not recruiting --> Completed | Trial completion date: Jan 2024 --> May 2024
- |||||||||| Journal: Treating Lows: Management of Orthostatic Hypotension. (Pubmed Central) - Sep 6, 2024
However, there's a lack of robust efficacy and safety evidence for all therapies. Building robust real-world and stratified clinical trials based on underlying pathophysiology may pave the way for further drug development and better clinical strategies and in this challenging unmet medical need.
- |||||||||| methamphetamine / Generic mfg.
Review, Journal: Pharmacological Treatments for Methamphetamine Use Disorder: Current Status and Future Targets. (Pubmed Central) - Sep 4, 2024
However, these drugs, plus medications like atomoxetine and varenicline, may be better served as treatments to ameliorate the psychotomimetic effects of METH or to reverse METH-induced cognitive deficits...In addition to screening these compounds in individuals with MUD, potential future directions include increased emphasis on sex differences in preclinical studies and utilization of pharmacogenetic approaches to determine if genetic variances are predictive of treatment outcomes. These future directions can help lead to better interventions for treating MUD.
- |||||||||| atomoxetine / Generic mfg., fluoxetine / Generic mfg., duloxetine / Generic mfg.
Preclinical, Journal: Estimation of Acceptable Daily Intake Values based on Modeling and In Vivo Mutagenicity of NDSRIs of Fluoxetine, Duloxetine and Atomoxetine. (Pubmed Central) - Sep 3, 2024
While the NDSRIs were all confirmed to be mutagenic in vitro (Ames assay) and in vivo (TGR) studies, the latter data indicated that the potency of the mutation response was > 4400 ng/day for all compounds- an order of magnitude higher than published regulatory limits for these NDSRIs. The approaches described herein can be used qualitatively to better categorize NDSRIs with respect to potency and inform whether they are in the ICH M7R2-designated Cohort of Concern.
- |||||||||| Qelbree (viloxazine) / Supernus Pharma, Knight Therap
Review, Journal: Attention-Deficit/Hyperactivity Disorder in Adults. (Pubmed Central) - Aug 22, 2024
For adults unable to take stimulants or with concurrent anxiety/depression, options include atomoxetine, viloxazine, and bupropion. To monitor for patient misuse or diversion of stimulants, physicians should consider employing controlled substance agreements and prescription drug monitoring programs.
- |||||||||| Qelbree (viloxazine) / Supernus Pharma, Knight Therap
Review, Journal: Quantification of ADHD medication in biological fluids of pregnant and breastfeeding women with liquid chromatography: a comprehensive review. (Pubmed Central) - Aug 22, 2024
This review aims (1) to compile and critically assess existing research on the transfer of ADHD medications into breast milk and the potential implications for nursing infants and (2) to provide a comprehensive overview and discussion of the literature regarding the quantification of methylphenidate, amphetamine, atomoxetine, viloxazine, guanfacine, clonidine and bupropion in the blood, urine, oral fluid, and breast milk with liquid chromatography...We illustrate the lack of methods to simultaneously monitor multiple ADHD medications as well as the lack of developed methods for breast milk. Finally, we highlight the need for continued research to refine our understanding of medication transfer into breast milk and potential risks, and to develop clinical guidelines to support mothers with ADHD in making informed choices regarding medication use during pregnancy and lactation.
- |||||||||| Journal: Molecular basis of human noradrenaline transporter reuptake and inhibition. (Pubmed Central) - Aug 21, 2024
Moreover, a potassium ion was observed within sodium-binding site 1 in the structure of the NET bound to desipramine under the KCl condition. Complemented by structural-guided biochemical analyses, our studies reveal the mechanism of substrate recognition, the alternating access of NET, and elucidate the mode of action of the four antidepressants.
- |||||||||| venlafaxine / Generic mfg., atomoxetine / Generic mfg., trazodone ER / Generic mfg.
Trial initiation date: Pharmacological Treatment Targeting Endotypic Traits of Obstructive Sleep Apnea (clinicaltrials.gov) - Aug 21, 2024
P1, N=66, Not yet recruiting,
Complemented by structural-guided biochemical analyses, our studies reveal the mechanism of substrate recognition, the alternating access of NET, and elucidate the mode of action of the four antidepressants. Initiation date: Apr 2024 --> Sep 2024
- |||||||||| atomoxetine / Generic mfg.
Preclinical, Journal: Long-life triclosan exposure induces ADHD-like behavior in rats via prefrontal cortex dopaminergic deficiency. (Pubmed Central) - Aug 14, 2024
Therefore, this study developed a long-life TCS-exposed rat model, an SH-SY5Y cell model, and an atomoxetine hydrochloride (ATX) treatment model to explore and validate the neurobehavioral mechanisms of TCS from multiple perspectives...These findings suggest that long-life TCS exposure causes ADHD-like behavior in male offspring rats through dopaminergic deficits. Furthermore, ATX treatment not only reduce symptoms in the rats, but also reveals valuable insights into the neurotoxic mechanisms induced by TCS.
- |||||||||| Qelbree (viloxazine) / Supernus Pharma, Knight Therap
Journal: Treatment Preferences of Adult Patients with Attention-Deficit/Hyperactivity Disorder - A Discrete Choice Experiment. (Pubmed Central) - Aug 12, 2024
Overall preferences for treatment profiles approximating centanafadine, lisdexamfetamine, atomoxetine, and viloxazine were estimated using adjusted total utilities...Accordingly, a profile resembling that of centanafadine would be preferred by an average patient compared to key competitors due to its favorable safety profile. These findings may help improve treatment decision-making, enhance treatment satisfaction, and foster adherence.
- |||||||||| Review, Journal: Pharmacological Treatment of Binge Eating Disorder and Frequent Comorbid Diseases. (Pubmed Central) - Aug 10, 2024
It is currently unclear whether the novel and promising glucagon, glucose-dependent insulinotropic polypeptide (GIP), and glucagon-like peptide 1 (GLP-1) receptor agonists like tirzepatide and retatrutide help with BED and its comorbidities. However, these compounds have been reported to reduce binge eating in individuals with obesity or overweight.
- |||||||||| atomoxetine / Generic mfg.
New P2 trial: Black Seed Oil in ADHD (clinicaltrials.gov) - Aug 7, 2024
P2, N=60, Not yet recruiting,
- |||||||||| methylphenidate tablet / Generic mfg., atomoxetine / Generic mfg.
Preclinical, Journal: Attenuated responses to attention-modulating drugs in the neuroligin-3R451C mouse model of autism. (Pubmed Central) - Aug 2, 2024
The absence of drug effects in Nlgn3R451C mice likely arises from their altered behavioural baseline and underlying neurobiology, highlighting caveats to the use of classic attention-modulating drugs across disorders and autism subsets. It further suggests that altered dopaminergic and/or norepinephrinergic systems may drive behavioural differences in the Nlgn3R451C mouse model of autism, supporting further targeted investigation.
- |||||||||| atomoxetine / Generic mfg.
Journal: Microstructural properties of attention-related white matter tracts are associated with the renewal effect of extinction. (Pubmed Central) - Aug 1, 2024
In this diffusion tensor imaging (DTI) analysis we investigated the relation between microstructural properties of attention-related WM tracts and ABA renewal propensity, under conditions of noradrenergic stimulation by means of the noradrenergic reuptake inhibitor atomoxetine, compared to placebo...In REN participants of both treatment groups, FA in several WM tracts showed a positive correlation with the ABA renewal level, suggesting higher renewal levels were associated with higher microstructural integrity. These findings point towards a relation between microstructural properties of attention-related WM tracts and the propensity for renewal that is not specifically dependent on noradrenergic processing.
|
